论文部分内容阅读
Background Cellular transplantation is emerging as a promising strategy for the treatment ofpostinfarction ventricular dysfunction, while the lower retention rate has been restricting the clinical application of cell therapy.The aim of this trail was to assess the safety and efficacy of intracoronary sequential infusion of autologous bone marrow mononuclear cells (BMMC) and mesenchymal stem cells (BMSC) in patients with acute myocardial infarction (AMI).